Wegovy Pill vs Injection for Weight Loss

The Wegovy pill and Wegovy injection contain the same active ingredient, semaglutide, under one prescribing label from the US Food and Drug Administration (FDA).¹ OASIS 4 reported an average 13.6% weight reduction at week 64 for the daily pill, while STEP 1 reported 14.9% at week 68 for the weekly pen in adults without diabetes.^2,3 These were separate trials and do not establish a head-to-head result. The main practical difference is routine. The pill has daily empty-stomach, water-only, and wait requirements explained by a prescriber or pharmacist. The injection is weekly at any time of day, with or without meals.¹

The Same Active Ingredient in Two Forms

Semaglutide is a glucagon-like peptide-1 (GLP-1) medicine and the active ingredient in both forms of Wegovy.¹ The molecule is the same, but the route into the body is different. A separate semaglutide weight-loss guide covers how the medication works.

A physician-led weight evaluation can examine insulin, leptin, ghrelin, cortisol, sex hormones, thyroid, metabolic rate, sleep, eating habits, exercise, and stress before the route is selected.

The combined Wegovy prescribing information covers the tablet and injection. This means both forms share drug-level safety considerations, including the boxed warning about thyroid C-cell tumors found in rodents. Human risk remains unknown.¹

The label contraindicates both forms for people with a personal or family history of medullary thyroid carcinoma, or with multiple endocrine neoplasia syndrome type 2.¹ Your physician screens for those factors before deciding whether either form belongs in your plan.

The same molecule does not make the two forms interchangeable in every situation. Their schedules differ. Some indications differ. Your physician also has to account for your medical history, current medications, daily routine, and response to treatment.

Side-by-Side Comparison of Oral and Injectable Wegovy

Self-pay figures in the final row come from NovoCare Pharmacy and were read on September 15, 2026.⁵

	Wegovy pill	Wegovy injection
Active ingredient	Semaglutide1	Semaglutide1
Form and schedule	Tablet taken once daily1	Pen used once weekly on the same day each week1
What the label requires for taking it	Empty stomach in the morning with water only, up to 4 ounces. The label requires a wait of at least 30 minutes before food, beverages, or other oral medications. A prescriber or pharmacist explains how this fits with other medicines.1	Any time of day, with or without meals.1
Label weight-management indication	Adults with obesity, or overweight with at least one weight-related condition1	Adults with obesity, or overweight with at least one weight-related condition. Also indicated for weight management from age 12.1
Other label indications	Reduced risk of major adverse cardiovascular events in certain adults with established cardiovascular disease and obesity or overweight1	The same cardiovascular indication, plus an indication for metabolic dysfunction-associated steatohepatitis (MASH)1
Main weight trial and length	OASIS 4, weight outcome at week 64, 307 adults without diabetes2	STEP 1, 68 weeks, 1,961 adults without diabetes3
Average weight change (vs placebo)	−13.6% vs −2.2% at week 642	−14.9% vs −2.4% at week 683
Most common side effects	Gastrointestinal adverse events occurred in 74.0% with oral semaglutide and 42.2% with placebo in OASIS 4.2	Nausea 44% vs 16% with placebo, diarrhea 30% vs 16%, vomiting 24% vs 6%, and constipation 24% vs 11%.1
Stopped for adverse reactions	6.8% with the Wegovy tablet vs 5.9% with placebo1	6.8% with the Wegovy injection vs 3.2% with placebo1
Self-pay price (NovoCare, read September 15, 2026)	Starts at $149 per month for the lowest strength. The second strength is $199, and the two highest strengths are $299. One month contains 30 tablets.5	New patients pay $199 per month for the first two monthly fills through December 31, 2026, then $349 per month. NovoCare states that pricing will be updated after December 31, 2026.5

Reading the OASIS 4 and STEP 1 Results

OASIS 4 and STEP 1 provide clear reference points for each Wegovy form, but the two averages came from different groups and different study schedules.

OASIS 4 enrolled 307 adults without diabetes. At week 64, average weight change was a 13.6% reduction with the daily Wegovy pill and a 2.2% reduction with placebo.² Both groups also received lifestyle interventions.

STEP 1 enrolled 1,961 adults without diabetes. At week 68, average weight change was a 14.9% reduction with the weekly injection and a 2.4% reduction with placebo.³ Lifestyle intervention was part of this trial as well.

The 13.6% and 14.9% figures are group averages at fixed weeks. They do not predict how much weight you will lose or how quickly your weight may change.

A physician reads these trial results alongside your response after treatment begins. Your weight trend, side effects, adherence, nutrition, and activity give the average a personal context. The prescription can then be reassessed based on what your body did.

The Indirect Comparison of Oral and Injectable Semaglutide

The 2026 Plotkin analysis compared the Wegovy pill and injection indirectly by using placebo as the common reference between OASIS 4 and STEP 1.⁴

The analysis found comparable efficacy across the outcomes assessed. The injection had a small numerical advantage of 1.01 percentage points for weight change, with a 95% confidence interval from −1.61 to 3.63 percentage points.⁴ The authors placed that estimate below the FDA threshold they used for clinical relevance.

Safety was described as broadly comparable.⁴ That finding came from an indirect statistical comparison of separate trials. Novo Nordisk funded the work. Five of the seven authors were employed by or advised Novo Nordisk, and the other two worked for a firm Novo Nordisk contracted to conduct the analysis.⁴

The result supports treating both forms as credible semaglutide options. It does not select one form for you. Your indication and ability to follow the routine may create a larger practical difference than the numerical gap in the analysis.

The Daily Tablet and Weekly Pen Routines

The tablet and pen ask for different habits, which can affect whether a prescription fits your week.

The Wegovy pill label requires the tablet once daily on an empty stomach in the morning. It specifies water only, with no more than 4 ounces. The label also requires a wait of at least 30 minutes before food, other drinks, or oral medications.¹ A pharmacist or prescriber explains how those conditions fit with an existing medication schedule.

The pill may suit an adult who wants to avoid injections and can follow the morning requirements consistently. A physician still has to confirm that the tablet carries the indication being treated.

The injection label specifies once-weekly use on the same day. It can be used at any time of day, with or without meals.¹ The pen may suit someone who prefers a weekly schedule or has morning medications that make the tablet routine difficult. A pharmacist can explain storage and device use when the pen is prescribed.

Your routine deserves a direct discussion during the consultation. A medication that repeatedly conflicts with breakfast, travel, work, or other prescriptions may be harder to follow over time.

Your history and changing lab pattern add context to the fixed label routine. Regular reassessment gives your physician a chance to revisit the form when your routine, response, or numbers change.

Label Indications for Each Wegovy Form

Both forms carry an adult weight-management indication and a cardiovascular risk-reduction indication for certain adults with established cardiovascular disease and obesity or overweight.¹

The injection carries two additional indications. It is approved for weight management beginning at age 12, and it has a MASH indication.¹ The tablets do not carry either indication.

These differences can decide the form before convenience enters the discussion. If the treatment is for an injection-only indication, the tablet does not provide the same label coverage. Your physician confirms the diagnosis and indication before comparing schedules.

A separate GLP-1 guide for men places semaglutide within a broader physician-led weight-management plan. The Foundayo vs Wegovy pill page covers the other oral GLP-1 comparison. The Ozempic vs Wegovy page handles that separate brand question.

Side Effects and Treatment Follow-Through

Gastrointestinal side effects were common in the main studies of both Wegovy forms, but rates from separate clinical trials cannot be compared directly.¹

OASIS 4 reported gastrointestinal adverse events in 74.0% of participants receiving oral semaglutide and 42.2% receiving placebo.² The Wegovy label reports that 6.8% of tablet participants stopped treatment because of adverse reactions, compared with 5.9% receiving placebo.¹

For the injection, the label lists nausea in 44%, diarrhea in 30%, vomiting in 24%, and constipation in 24%. Placebo rates were 16%, 16%, 6%, and 11%, respectively.¹ Adverse reactions caused 6.8% of participants receiving the injection to stop, compared with 3.2% receiving placebo.¹

Those figures do not show that one form has fewer side effects. They show that tolerability needs active follow-up with either form. Your physician tracks the symptoms you experience, their timing, and whether they interfere with eating, hydration, other medication, or continued treatment.

Self-Pay Prices for the Pill and Pen

NovoCare listed different self-pay prices for the tablet and pen when read on September 15, 2026.⁵ The tablet ranged from $149 to $299 per month depending on its position in the strength sequence.

New pen patients paid $199 per month for the first two monthly fills through December 31, 2026, followed by $349 per month.⁵ NovoCare states that pen pricing will be updated after that date. A broader GLP-1 cost guide covers the other line items that can affect treatment cost.

Choosing a Form with Your Physician

A physician weighs indication, schedule, tolerability, other medications, and self-pay cost when choosing between the Wegovy pill and injection.

The pill may fit if you have an adult indication, prefer tablets, and can follow its morning conditions. The weekly pen may fit if you prefer fewer administration days, need an indication carried only by the injection, or cannot make the tablet routine work with other morning medication.

The decision can also change after treatment starts. Persistent side effects, difficulty following the schedule, a change in diagnosis, or a change in price can alter the balance. The Wegovy label includes switching between the tablet and injection in both directions.¹ Your prescriber determines whether a switch fits your care and sets the transition.

A prescribing consultation should leave you with a clear reason for the route selected and a plan for tracking your response.

The Opt Take on Wegovy Pill vs Injection

The medication decision begins after a physician understands your labs, medical history, weight pattern, schedule, and goals. A prescription alone cannot show whether insulin regulation, hormones, sleep, inflammation, nutrition, or another factor is affecting your progress.

Opt Health begins with a panel of 55+ biomarkers. A physician reads those results against your symptoms and current medications, then builds a personalized plan. The initial panel can be completed at home or at a local partner lab, and the results are reviewed during a 1:1 physician consultation. Full labs and a physician consultation repeat every three to four months, allowing the plan to change when your numbers or response change.

That loop is useful with either Wegovy form. Your physician can track weight, tolerability, adherence, and related biomarkers instead of relying on a single trial average.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

Self-pay prices and offer terms can change without notice. Verify current figures on the NovoCare Wegovy pricing page before relying on them.

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.